

XCYTE THERAPIES INC
Form SC 13G/A
December 08, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)

XCYTE Therapies, Inc.

(Name of Issuer)

Common Stock, .001 Par Value

(Title of Class of Securities)

98389F309

(CUSIP Number)

with a copy to:

Austin W. Marxe	Allen B. Levithan, Esq.
527 Madison Avenue, suite 2600	Lowenstein Sandler PC
New York, New York 10022	65 Livingston Avenue
	Roseland, N.J. 07068
	(973) 597-2406

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

November 30, 2005
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

_____ Rule 13d-1(b)
 x Rule 13d-1(c)
_____ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be ?filed? for the purpose of Section 18 of the Securities
Exchange Act of 1934 (?Act?) or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).

Cusip No. 98389F309 13G Page 2 of 6
Pages

1.Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only):

Austin W. Marxe and David M. Greenhouse

Edgar Filing: XCYTE THERAPIES INC - Form SC 13G/A

2. Check the Appropriate Box if a Member of a Group (See Instructions):

- (a) [] Not Applicable
(b) []

3. SEC Use Only

4. Source of Funds (See Instructions): 00

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

Not Applicable

6. Citizenship or Place of Organization: United States

Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power: 0
8. Shared Voting Power: 3,481,361*
9. Sole Dispositive Power: 0
10. Shared Dispositive Power:

3,481,361*___

11. Aggregate Amount Beneficially Owned by Each Reporting Person:

3,481,361*

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares

(See Instructions): Not Applicable

13. Percent of Class Represented by Amount in Row (11): 17.7%*

14. Type of Reporting Person (See Instructions): IA, IN

* This is a joint filing by Austin W. Marxe (?Marxe?) and David M. Greenhouse (?Greenhouse?). Marxe and Greenhouse share sole voting and investment power over 729,948 shares of Common Stock owned by Special Situations Cayman Fund, L.P., 2,717,403 shares of Common Stock owned by Special Situations Fund III, L.P., and 34,010 shares of Common Stock owned by Special Situations Life Sciences Fund, L.P. See Items 2 and 4 of this Schedule for additional information.

Page 3 of 6 Pages

Item 1. Security and Issuer:

- (a) XCYTE Therapies, Inc.
(b) 1124 Columbia Street, Suite 130, Seattle, WA 98104

Item 2. (a) Name of Person Filing:

The persons filing this report are Austin W. Marxe (?Marxe?) and David M. Greenhouse (?Greenhouse?), who are the controlling principals of AWM Investment Company, Inc. (?AWM?), the general partner of and investment adviser to Special Situations Cayman Fund, L.P. (?Cayman?). AWM also serves as the general partner of MGP Advisers Limited Partnership (?MGP?), the general partner of and investment adviser to Special Situations Fund III, L.P. (?SSF3?). Marxe and Greenhouse are also members of LS Advisers, L.L.C., the general partner of and investment adviser to Special Situations Life Sciences Fund, L.P.

Edgar Filing: XCYTE THERAPIES INC - Form SC 13G/A

(?Life Sciences?) (SSF3, Cayman and Life Sciences will hereafter be referred to as, the ?Funds?). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature.

(b) Address of Principal Business Office or, if none, Residence:

The principal business address for Marxe and Greenhouse is 527 Madison Avenue, Suite 2600, New York, NY 10022.

(c) Citizenship:

Austin W. Marxe and David M. Greenhouse are United States citizens.

(d) Title of Class of Securities: Common Stock.

(e) CUSIP Number: 98389F309.

Item 3. If this statement is filed pursuant to §240.13d-1(b) or 240.13d-2(b), check whether

the person filing is a: Not Applicable

- (a) Broker or Dealer registered under section 15 of the Act;
- (b) Bank as defined in section 3(a) (6) of the Act;
- (c) Insurance Company as defined in section 3(a) (19) of the Act;
- (d) Investment Company registered under section 8 of the Investment Company Act of 1940;
- (e) An Investment Adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

Page 4 of 6 Pages

(g) A parent holding company or control person in accordance with §240.13d-

1(b)(1)(ii)(G);

(h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance

Act;

(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j) Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership:

(a) Amount Beneficially Owned: Messrs. Marxe and Greenhouse beneficially own a total of 3,481,361 shares of Common Stock. This amount includes 729,948 shares of Common Stock owned by Cayman, 2,717,403 shares of Common Stock owned by SSF3 and 34,010 shares of Common Stock owned by Life Sciences.

(b) Percent of Class: Messrs. Marxe and Greenhouse beneficially own 17.7% of the shares outstanding. Cayman owns 3.7% of the outstanding shares; SSF3 owns 13.8% of the outstanding shares and Life

Edgar Filing: XCYTE THERAPIES INC - Form SC 13G/A

Sciences owns 0.2% of the outstanding shares.

(c) Number of Shares as to which the person has:

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote: 3,481,361

(iii) Sole power to dispose or to direct the disposition of:
0

(iv) Shared power to dispose or to direct the disposition
of: 3,481,361

Item 5. Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ___.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security being Reported on By the Parent Holding Company:
Not Applicable.

Item 8. Identification and Classification of Members of the Group: Not applicable

Page 5 of 6 Pages

Item 9. Notices of Dissolution of Group: Not applicable.

Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Edgar Filing: XCYTE THERAPIES INC - Form SC 13G/A

Dated: December 5, 2005

/s/ Austin W. Marxe
AUSTIN W. MARXE

/s/David M Greenhouse
DAVID M. GREENHOUSE

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

Page 6 of 6 Pages

JOINT FILING AGREEMENT

Austin W. Marxe and David M. Greenhouse hereby agree that the Schedule 13G to which this agreement is attached is filed on behalf of each of them.

/s/_Austin W. Marxe
Austin W. Marxe

/s/_David M. Greenhouse
David M. Greenhouse

-6-

S5313/1
1319328.02